Introduction and Overview

Cloud drug discovery refers to the establishment of cloud computing technologies and infrastructure to conduct drug development pipeline steps, from target identification and compound screening to preclinical and clinical data analysis. In this approach, computational power, data storage and analysis tools are provided by cloud technologies instead of proprietary systems.¹

Cloud computing accelerates drug design by integrating massive datasets, supporting data exchange for collaboration and running complex simulations at scale. By leveraging high-performance computing, AI/ML algorithms and secure data sharing environments, researchers can identify promising drug candidates more quickly and cost-effectively than through traditional approaches.¹

Cloud-based drug discovery is a key step towards digital transformation in the pharmaceutical industry. The infrastructure empowers pharmaceutical companies through efficient data storage and workflow automation, shortening timelines in increasingly complex drug discovery and development research.¹

Why Move Drug Discovery to the Cloud?

Overcoming Scale and Complexity

Drug discovery workflows involving genomics, proteomics, cheminformatics and large-scale phenotypic screening yield vast and heterogeneous datasets that in-house servers cannot manage efficiently. Furthermore, pipelines with an  in silico component for molecular modelling and virtual screening of billions of compounds demand massive computational power. Cloud platforms are more suitable for these tasks, as they provide virtually unlimited storage and scalable computing resources to process these datasets.²

Addressing Bottlenecks in Traditional Infrastructure

Many research environments face challenges in data management due to specialized hardware, fragmented data siloes and rigid IT infrastructures. These barriers limit data exchange across institutions and the adoption of new technologies. Cloud-based platforms address these issues by providing standardized data-sharing environments, which support the rapid deployment of new computational tools and data structures.³

Market Drivers and Innovation Pressures

Migration to the cloud paves the way for more agile, data-driven and transparent drug discovery workflows needed to accelerate the delivery of life-saving products to the market. Cloud-based infrastructures will be particularly instrumental for pandemics that require urgent intervention. Personalized medicine research, which integrates diverse patient datasets, from omics to electronic health records, can also be streamlined through cloud-based infrastructures.³

How the Cloud is Transforming Biotech and Pharmaceutical Companies

Democratization of Access

While established pharmaceutical companies may have access to resources and tools to oversee their pipelines, startups and medium-sized companies may lack the capital to build and maintain expensive high-performance computing clusters. In contrast, cloud computing democratizes these resources, allowing smaller firms to leverage bioinformatics tools, AI-driven drug discovery platforms and cheminformatics without significant investment.¹

Real-Time Collaboration and Distributed Research

A key strength of the cloud is its data standardization, which empowers collaboration across research teams, even if they are dispersed geographically.

Cloud-driven platforms allow scientists to share design, simulation and analysis datasets across all parties involved in the drug development lifecycle. Furthermore, shared workspaces support collaborative drug design, cross-site data integration and audit trailing of research outputs. ⁴

This global connectivity accelerates discovery, improves reproducibility and helps build trust among partners, CROs and academic collaborators.

R&D Agility and Scalability

R&D is inherently dynamic, with computational demands varying dramatically between stages. Cloud platforms provide flexible resources for computationally expensive simulations, high-throughput virtual screening or large-scale clinical data analysis. ⁵

This flexibility ensures that research teams are adaptable and can respond quickly to new hypotheses, changing priorities, methodological errors or translational failures.

Key benefits of Cloud-Based Drug Discovery

Speed and Efficiency

• Cloud-based platforms accelerate compound screening, target validation and identification of drug candidates⁶
• They can integrate AI-powered algorithms to detect potential leads and predict late-stage failures⁷

Flexibility and Scalability

• Researchers can scale up resources for demanding tasks such as molecular modeling, virtual screening or multi-omics analysis⁸
• Cloud platforms ensure that resources are scaled down when no longer needed, avoiding unnecessary use⁹

Enhanced Collaboration and Smarter Decision-Making

• By centralizing data in secure cloud environments, global research teams gain real-time access to results from a single platform¹
• AI/ML-driven insights and advanced cloud analytics equip scientists with the knowledge to optimize compound screening workflows and reassess prioritization strategies¹

Security and Compliance

• The privacy of sensitive biomedical data is asserted in cloud-based drug research through robust data protection measures such as encryption, access controls and audit trails¹⁰
• Compliance frameworks of cloud platforms are aligned with FDA 21 CFR Part 11, HIPAA, GDPR and other regional standards to guide pharmaceutical organizations in meeting regulatory requirements¹¹

Core Tools and Technologies Powering Cloud Drug Discovery

Cloud Computing Infrastructure

A robust computing infrastructure forms the foundation of cloud-based drug discovery. Several platforms deliver scalable compute and storage environments optimized for life sciences. Furthermore, computational biology software tools for molecular dynamics, virtual screening and clinical trial data management are designed to be compatible as cloud-native drug discovery solutions.¹²

Artificial Intelligence and Machine Learning

Cloud-native AI platforms support drug discovery workflows by accelerating target identification, compound scoring and drug repurposing. Machine learning models trained on large-scale datasets can predict pharmacokinetics, toxicity and efficacy earlier in the pipeline, ultimately reducing attrition.⁷

Integration with cloud systems ensures continuous model retraining. These systems also support federated learning, a machine learning method enabling collaborative model training across global sites without disclosing sensitive information.¹³

Computational and Quantum Technologies

Cloud platforms also host advanced computational chemistry and molecular modeling tools, enabling simulation of protein-ligand interactions, docking studies and dynamics at scale. Thus, researchers can virtually screen millions of compounds faster than traditional lab-based methods. In addition, the emergence of quantum computing creates an opportunity to model complex quantum mechanical interactions between drugs and proteins with higher accuracy.¹⁴

Bioinformatics and Cheminformatics Platforms

Cloud-based bioinformatics platforms can expedite the discovery of genomics and multi-omics-based biomarkers, as well as drug screening for large populations. Chemoinformatics software can complement these tools with structure–activity relationship (SAR) studies, closing the gap between genomics and chemical structure analysis in drug discovery.¹⁵

Relationship to ELNs and LIMSs

Foundation for Digital Workflows

Data digitization has gained importance in R&D workflows in drug development. To that end, Electronic Lab Notebooks (ELNs) and Laboratory Information Management Systems (LIMSs) capture and organize a wide range of essential research data, including experimental protocols, sample metadata, assay results and analytical records. ELNs and LIMSs ensure data traceability throughout the drug development process by standardizing data entry and management.¹⁶

Enhanced Collaboration Through Cloud Integration

ELNs and LIMSs should be democratized by integrating them into cloud infrastructure. Researchers across organizations gain secure access to experiment records and incorporate real-time updates. The combination of centralized reporting and data sharing, supported by advanced analytics tools, AI engines and modeling software, has the potential to transform ELNs and LLMs into dynamic and interoperable research hubs.¹⁶

Compliance and Audit Readiness

Cloud infrastructure harbors frameworks aligning with regulatory standards, including FDA 21 CFR Part 11, EMA and GLP/GMP guidelines.¹⁷ These frameworks have powerful features, such as:

• Version control that improves the traceability of data
• Role-based access with user-specific permissions to establish modular data structures
• Immutable audit trails that reveal information about each data entry

These features collectively reduce administrative overhead while maintaining the security and credibility of research records.

Applications and Use Cases

Preclinical and Screening

Cloud platforms have immense potential to accelerate preclinical stages of drug discovery.

• DMPK and ADME modelling in the cloud allows researchers to predict adverse effects and therapeutic potential earlier, reducing costly late-stage attrition18
• The deployment of high-throughput screening platforms on the cloud accelerates the evaluation of vast compound libraries, with parallelized screening and scoring functionalities⁸

These improvements can accelerate lead discovery and optimization, while equipping researchers with greater confidence in the results before conducting in vivo studies.

Collaborative and Remote Research

Cloud ecosystems foster multi-partner R&D collaborations, where pharmaceutical companies, CROs and academic institutions can collaborate seamlessly.

Real-time remote drug design technology allows globally distributed teams to share datasets, run joint simulations and co-analyze results in secure environments. Thus, drug discovery and development expertise can be fully leveraged across institutions without geographic barriers.³

Omics and Data-Driven Approaches

A key strength of cloud-based drug discovery is the ability to store and organize massive omics datasets.

Cloud-based genomics analysis assists target discovery by linking genetic variations to disease pathways. Bioinformatics tools can be scaled to accommodate transcriptomics, proteomics and metabolomics, which can be used to discover novel biomarkers and stratify patients.⁸

In addition, multi-omics datasets can be complemented with phenotypic screening for more holistic insights into disease mechanisms and drug evaluation.¹⁹

Challenges and Considerations

Data Security and Privacy

Cloud-based drug discovery platforms handle sensitive datasets, including clinical trial data, genomic information and proprietary compound libraries. Protecting these assets requires adherence to strict privacy frameworks, such as HIPAA, GDPR and regional data protection laws. These laws can guide drug innovators, encouraging robust encryption, identity management and continuous monitoring to safeguard data against breaches.¹¹

Integration with Legacy Systems

Despite the advent of cloud platforms, many pharmaceutical organizations still rely on long-established IT infrastructures and laboratory systems. For these companies, migration of resources to the cloud presents challenges in interoperability, data transfer and workforce upskilling.¹

Integrating legacy ELNs, LIMSs and proprietary databases with cloud platforms may require data refinement and reformatting. The process can be further hindered by the skills gaps in cloud-native development and DevOps. These issues highlight an urgent need for employee training programs alongside technology deployment.¹

Regulatory and Compliance Management

When selecting a cloud platform for data transfer, drug innovators must ensure that the platform provides comprehensive documentation, system validation and immutable audit trails to align with FDA 21 CFR Part 11, EMA, GLP/GMP and other standards. Adopting drug discovery pipelines to the cloud necessitates constant communication across IT, compliance officers and research teams to ensure transparency and regulatory readiness.¹¹

Conclusion

Cloud computing can address several challenges in today’s drug discovery landscape by delivering the scalability, speed and flexibility needed to manage complex biomedical data. It accelerates screening, supports global collaboration and integrates multi-omics insights, while overcoming traditional barriers like costly hardware and siloed data.

Drug development's reliance on cloud infrastructure will continue to grow with the implementation of technologies such as federated learning and quantum computing, which can expand computational possibilities. The cloud also continues to drive a paradigm shift in companies towards more centralized and secure management of sensitive data, with compliance frameworks propelling them towards market readiness.

References

1. Bonde B. Edge, Fog, and Cloud Against Disease: The Potential of High-Performance Cloud Computing for Pharma Drug Discovery. High Performance Computing for Drug Discovery and Biomedicine 2023:181-202.
2. Lin Z, Zou J, Liu S, Peng C, Li Z, Wan X, et al. A cloud computing platform for scalable relative and absolute binding free energy predictions: New opportunities and challenges for drug discovery. J Chem Inf Model 2021;61(6):2720-2732.
3. Gomase VS, Ghatule AP, Sharma R, Sardana S, Dhamane SP. Cloud Computing Facilitating Data Storage, Collaboration, and Analysis in Global Healthcare Clinical Trials. Rev Recent Clin Trials 2025.
4. Spjuth O, Frid J, Hellander A. The machine learning life cycle and the cloud: implications for drug discovery. Expert Opin Drug Discov 2021;16(9):1071-1079.
5. Schuhmacher A, Gatto A, Kuss M, Gassmann O, Hinder M. Big Techs and startups in pharmaceutical R&D–A 2020 perspective on artificial intelligence. Drug Discov Today 2021;26(10):2226-2231.
6. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature 2023;616(7958):673-685.
7. Rehan H. Advancing cancer treatment with AI-driven personalized medicine and cloud-based data integration. J Mach Learn Res 2024;4(2):1-40.
8. Koppad S, B A, Gkoutos GV, Acharjee A. Cloud computing enabled big multi-omics data analytics. Bioinform Biol Insights 2021;15:11779322211035921.
9. Kutzner C, Kniep C, Cherian A, Nordstrom L, Grubmüller H, de Groot BL, et al. GROMACS in the cloud: A global supercomputer to speed up alchemical drug design. J Chem Inf Model 2022;62(7):1691-1711.
10. Barati M, Aujla GS, Llanos JT, Duodu KA, Rana OF, Carr M, et al. Privacy-aware cloud auditing for GDPR compliance verification in online healthcare. IEEE Trans Industr Inform 2021;18(7):4808-4819.
11. Miller M, Zaccheddu N. Light for a Potentially Cloudy Situation: Approach to Validating Cloud Computing Tools. Biomed Instrum Technol 2021;55(2):63-68.
12. Taneja A. Secure Cloud Infrastructures for Deploying AI-Powered Drug Discovery Pipelines. Int Res J Eng Technol 2022;3(4):43-52.
13. Oldenhof M, Ács G, Pejó B, Schuffenhauer A, Holway N, Sturm N, et al. Industry-scale orchestrated federated learning for drug discovery. AAAI 2023:15576-15584.
14. Zinner M, Dahlhausen F, Boehme P, Ehlers J, Bieske L, Fehring L. Quantum computing's potential for drug discovery: Early-stage industry dynamics. Drug Discov Today 2021;26(7):1680-1688.
15. Ramapraba PS, Babu BR, Paul NRR, Sharmila V, Babu VR, Ramya R, et al. Implementing cloud computing in drug discovery and telemedicine for quantitative structure-activity relationship analysis. Int J Electr Comput Eng 2025;15(1):1132-1141.
16. Edfeldt K, Edwards AM, Engkvist O, Guenther J, Hartley M, Hulcoop DG, et al. A data science roadmap for open science organizations engaged in early-stage drug discovery. Nat Commun 2024;15(1):5640.
17. Ullagaddi P. Cloud validation in pharma: Compliance and strategic value. Int J Bus Manag 2024;9:11-17.
18. Bos PH, Houang EM, Ranalli F, Leffler AE, Boyles NA, Eyrich VA, et al. AutoDesigner, a De Novo Design Algorithm for rapidly exploring large chemical space for lead optimization: application to the design and synthesis of d-Amino acid oxidase inhibitors. J Chem Inf Model 2022;62(8):1905-1915.
19. Sexton JZ, Fursmidt R, O’Meara MJ, Omta W, Rao A, Egan DA, et al. Machine learning and assay development for image-based phenotypic profiling of drug treatments. AGM 2023.